211 related articles for article (PubMed ID: 21309036)
1. Recurrence and variability of germline EPCAM deletions in Lynch syndrome.
Kuiper RP; Vissers LE; Venkatachalam R; Bodmer D; Hoenselaar E; Goossens M; Haufe A; Kamping E; Niessen RC; Hogervorst FB; Gille JJ; Redeker B; Tops CM; van Gijn ME; van den Ouweland AM; Rahner N; Steinke V; Kahl P; Holinski-Feder E; Morak M; Kloor M; Stemmler S; Betz B; Hutter P; Bunyan DJ; Syngal S; Culver JO; Graham T; Chan TL; Nagtegaal ID; van Krieken JH; Schackert HK; Hoogerbrugge N; van Kessel AG; Ligtenberg MJ
Hum Mutat; 2011 Apr; 32(4):407-14. PubMed ID: 21309036
[TBL] [Abstract][Full Text] [Related]
2. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
[TBL] [Abstract][Full Text] [Related]
3. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
[TBL] [Abstract][Full Text] [Related]
4. EPCAM germline and somatic rearrangements in Lynch syndrome: identification of a novel 3'EPCAM deletion.
Spaepen M; Neven E; Sagaert X; De Hertogh G; Beert E; Wimmer K; Matthijs G; Legius E; Brems H
Genes Chromosomes Cancer; 2013 Sep; 52(9):845-54. PubMed ID: 23801599
[TBL] [Abstract][Full Text] [Related]
5. Analysis of EPCAM protein expression in diagnostics of Lynch syndrome.
Kloor M; Voigt AY; Schackert HK; Schirmacher P; von Knebel Doeberitz M; Bläker H
J Clin Oncol; 2011 Jan; 29(2):223-7. PubMed ID: 21115857
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Japanese Lynch syndrome patient with large deletion in the 3' region of the EPCAM gene.
Eguchi H; Kumamoto K; Suzuki O; Kohda M; Tada Y; Okazaki Y; Ishida H
Jpn J Clin Oncol; 2016 Feb; 46(2):178-84. PubMed ID: 26613680
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification.
Musulen E; Blanco I; Carrato C; Fernandez-Figueras MT; Pineda M; Capella G; Ariza A
Hum Pathol; 2013 Mar; 44(3):412-6. PubMed ID: 23026194
[TBL] [Abstract][Full Text] [Related]
8. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.
Mur P; Pineda M; Romero A; Del Valle J; Borràs E; Canal A; Navarro M; Brunet J; Rueda D; Ramón Y Cajal T; Lázaro C; Caldés T; Blanco I; Soto JL; Capellá G
Clin Genet; 2014 Mar; 85(3):260-6. PubMed ID: 23530899
[TBL] [Abstract][Full Text] [Related]
9. EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients.
Guarinos C; Castillejo A; Barberá VM; Pérez-Carbonell L; Sánchez-Heras AB; Segura A; Guillén-Ponce C; Martínez-Cantó A; Castillejo MI; Egoavil CM; Jover R; Payá A; Alenda C; Soto JL
J Mol Diagn; 2010 Nov; 12(6):765-70. PubMed ID: 20864635
[TBL] [Abstract][Full Text] [Related]
10. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases.
Rumilla K; Schowalter KV; Lindor NM; Thomas BC; Mensink KA; Gallinger S; Holter S; Newcomb PA; Potter JD; Jenkins MA; Hopper JL; Long TI; Weisenberger DJ; Haile RW; Casey G; Laird PW; Le Marchand L; Thibodeau SN
J Mol Diagn; 2011 Jan; 13(1):93-9. PubMed ID: 21227399
[TBL] [Abstract][Full Text] [Related]
11. Alu in Lynch syndrome: a danger SINE?
Hitchins MP; Burn J
Cancer Prev Res (Phila); 2011 Oct; 4(10):1527-30. PubMed ID: 21972078
[TBL] [Abstract][Full Text] [Related]
12. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.
Kempers MJ; Kuiper RP; Ockeloen CW; Chappuis PO; Hutter P; Rahner N; Schackert HK; Steinke V; Holinski-Feder E; Morak M; Kloor M; Büttner R; Verwiel ET; van Krieken JH; Nagtegaal ID; Goossens M; van der Post RS; Niessen RC; Sijmons RH; Kluijt I; Hogervorst FB; Leter EM; Gille JJ; Aalfs CM; Redeker EJ; Hes FJ; Tops CM; van Nesselrooij BP; van Gijn ME; Gómez García EB; Eccles DM; Bunyan DJ; Syngal S; Stoffel EM; Culver JO; Palomares MR; Graham T; Velsher L; Papp J; Oláh E; Chan TL; Leung SY; van Kessel AG; Kiemeney LA; Hoogerbrugge N; Ligtenberg MJ
Lancet Oncol; 2011 Jan; 12(1):49-55. PubMed ID: 21145788
[TBL] [Abstract][Full Text] [Related]
13. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.
Ligtenberg MJ; Kuiper RP; Chan TL; Goossens M; Hebeda KM; Voorendt M; Lee TY; Bodmer D; Hoenselaar E; Hendriks-Cornelissen SJ; Tsui WY; Kong CK; Brunner HG; van Kessel AG; Yuen ST; van Krieken JH; Leung SY; Hoogerbrugge N
Nat Genet; 2009 Jan; 41(1):112-7. PubMed ID: 19098912
[TBL] [Abstract][Full Text] [Related]
14. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.
Kovacs ME; Papp J; Szentirmay Z; Otto S; Olah E
Hum Mutat; 2009 Feb; 30(2):197-203. PubMed ID: 19177550
[TBL] [Abstract][Full Text] [Related]
15. The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors.
Huth C; Kloor M; Voigt AY; Bozukova G; Evers C; Gaspar H; Tariverdian M; Schirmacher P; von Knebel Doeberitz M; Bläker H
Mod Pathol; 2012 Jun; 25(6):911-6. PubMed ID: 22388758
[TBL] [Abstract][Full Text] [Related]
16. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion.
Lynch HT; Riegert-Johnson DL; Snyder C; Lynch JF; Hagenkord J; Boland CR; Rhees J; Thibodeau SN; Boardman LA; Davies J; Kuiper RP; Hoogerbrugge N; Ligtenberg MJ
Am J Gastroenterol; 2011 Oct; 106(10):1829-36. PubMed ID: 21769135
[TBL] [Abstract][Full Text] [Related]
17. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients.
Ligtenberg MJ; Kuiper RP; Geurts van Kessel A; Hoogerbrugge N
Fam Cancer; 2013 Jun; 12(2):169-74. PubMed ID: 23264089
[TBL] [Abstract][Full Text] [Related]
18. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers.
Kang SY; Park CK; Chang DK; Kim JW; Son HJ; Cho YB; Yun SH; Kim HC; Kwon M; Kim KM
Int J Cancer; 2015 Apr; 136(7):1568-78. PubMed ID: 25110875
[TBL] [Abstract][Full Text] [Related]
19. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
[TBL] [Abstract][Full Text] [Related]
20. Toward a better definition of EPCAM deletions in Lynch Syndrome: Report of new variants in Italy and the associated molecular phenotype.
Cini G; Quaia M; Canzonieri V; Fornasarig M; Maestro R; Morabito A; D'Elia AV; Urso ED; Mammi I; Viel A
Mol Genet Genomic Med; 2019 May; 7(5):e587. PubMed ID: 30916491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
